Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells

Wang, Kun; Bodempudi, Vidya; Liu, Zhengian; Borrego-Diaz, Emma; Yamoutpoor, Farnaz; Meyer, Anna; Woo, Richard A.; Pan, Weihong; Dudek, Arkadiusz Z.; Olyaee, Mojtaba; Esfandyari, Tuba; Farassati, Faris

doi:10.1371/journal.pone.0033214

Cited by 40 publications

(49 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wang and colleagues (80) have been evaluating the effects of direct targeting of mesothelin on the viability of cancer cells as the first step toward developing a novel therapeutic strategy. They have shown that the gene-specific silencing for mesothelin by distinct methods (siRNA and miRNA) decreased viability of ovarian cancer Skov3 and Ovcar-5 cell lines.…”

Section: Serum Markers For Ovarian Cancermentioning

confidence: 99%

“…The molecular mechanism of reduced invasiveness was connected to the reduced expression of b-catenin, an important marker of epithelial-mesenchymal transition (EMT). Ero1, a protein involved in clearing unfolded proteins and a member of the ER stress (endoplasmic reticulum-stress) pathway, was also markedly reduced (80).…”

Section: Serum Markers For Ovarian Cancermentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Kobayashi

Ueda

Matsuzaki

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Serum tumor markers have a major role in the screening, diagnosis, and monitoring of most of the gynecologic cancers. Ovarian cancer is one of the deadliest of the group because it is so frequently asymptomatic until it has advanced to an untreatable stage. Even serum cancer antigen-125 (CA-125), clinically one of the most reliable serum markers for ovarian cancer, is elevated in only half of early-stage still-treatable tumors. Because of the very low prevalence of ovarian cancer in the general population, at present, there is no cost-effective imaging or simple microscopic screening test for ovarian cancer as there is for breast and cervical cancers. However, recent proteomics and nucleic acid-based analyses have shown great promise for the discovery of new and more useful serum biomarkers, which cumulatively might provide such a screening tool. In this review, we will discuss both the currently used serum tumor markers for screening, diagnosis, monitoring of ovarian cancer, and the novel biomarkers that are now under investigation and validation.

show abstract

Section: Serum Markers For Ovarian Cancermentioning

confidence: 99%

Section: Serum Markers For Ovarian Cancermentioning

confidence: 99%

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Kobayashi

Ueda

Matsuzaki

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Mesothelin, a differentiation antigen normally present on mesothelial cells, is highly expressed in several human cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. As a result, mesothelin has been evaluated as a diagnostic biomarker and an immunotherapeutic target (Wang et al, 2012). It is intriguing to note that a novel paper sensor aiming at the detection of mesothelin was recently invented (www.societyforscience.org/intelisef2012).…”

Section: Carbon Nanotubes (Cnts)mentioning

confidence: 99%

Detection of Cancer Biomarkers With Nanotechnology

Zhang

et al. 2013

American Journal of Biochemistry and Biotechnology

View full text Add to dashboard Cite

Early detection of cancer biomarkers with high precision is critically important for cancer therapy. A variety of sensors based on different nanostructured materials have attracted intensive research interest due to their potential for highly sensitive and selective detection of cancer biomarkers. This review covers the use of a variety of nanostructured materials, including carbon nanotubes, silicon nanowires, gold nanoparticles and quantum dots, in the fabrication of sensors. Emphases are placed on how the detection systems work and what detection limits can be achieved. Some assays described in this review outperform established methods for cancer biomarker detection. It is highly promising that these sensors would soon move into commercial-scale production and find routine use in hospitals.

show abstract

“…The function of mesothelin in cancer is still unclear. However, results of recent studies have suggested that the mesothelin may play a role of tumor progression in vitro [8][9][10][11] and in vivo [11,12] .…”

Section: Introductionmentioning

confidence: 99%

Clinical impacts of mesothelin expression in gastrointestinal carcinomas

Einama¹,

Kawamata²,

Kamachi³

et al. 2016

WJGP

View full text Add to dashboard Cite

Mesothelin, C-ERC/mesothelin is a 40-kDa cell surface glycoprotein that is normally present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. Moreover, mesothelin has been shown to be overexpressed in several human cancers, including virtually all mesothelioma and pancreatic cancer, approximately 70% of ovarian cancer and extra bile duct cancer, and 50% of lung adenocarcinomas and gastric cancer. The full-length human mesothelin gene encodes the primary product, a 71-kDa precursor protein. The 71-kDa mesothelin precursor is cleaved into two products, 40-kDa C-terminal fragment that remains membranebound via glycosylphosphatidylinositol anchor, and a 31-kDa N-terminal fragment, megakaryocyte potentiating factor, which is secreted into the blood. The biological functions of mesothelin remain largely unknown. However, results of recent studies have suggested that the mesothelin may play a role of cell proliferation and migration. In pancreatic cancer, mesothelin expression was immunohistochemically observed in all cases, but absent in normal pancreas and in chronic pancreatitis. Furthermore, the expression of mesothelin was correlated with an poorer patient outcome in several human cancers. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. The present review discusses the expression and function of mesothelin in cancer cells and the utility of mesothelin as World J Gastrointest Pathophysiol 2016 May 15; 7(2): 218-222 ISSN 2150-5330 (online)

show abstract

Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells

Cited by 40 publications

References 51 publications

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Detection of Cancer Biomarkers With Nanotechnology

Clinical impacts of mesothelin expression in gastrointestinal carcinomas

Contact Info

Product

Resources

About